A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Completed · Phase 1/Phase 2

Conditions studied: Non-small Cell Lung Cancer(NSCLC)

In brief

The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.

Key facts

Study ID

NCT01712217

Run by

Astex Pharmaceuticals, Inc.

People needed

220

Starts

2012-10-01

Expected to finish

2017-05-16

Last updated by the study team

2024-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women 18 years of age or older
• Must have Non-small Cell Lung Cancer with ALK+ mutation or other mutations or rearrangements potentially sensitive to crizotinib
• Measurable disease
• Must have been receiving or have received crizotinib
• Have adequate cardiac, bone marrow, liver and kidney function
• Must be willing and able to provide written informed consent and comply with the protocol and study procedures

You may not qualify if…

• Prior anti-cancer treatment with any HSP90 inhibitor
• Have received chemotherapy, radiation therapy or other anticancer treatment other than crizotinib within 3 weeks prior to the first dose of study drug
• Prior malignancy other than adequately treated basal or squamous cell carcinoma of the skin, superficial bladder cancer, low-grade cervical cancer, non-metastatic prostate cancer, or have been disease-free for at least 3 years
• Abnormal heart function
• Presence of a life-threatening illness, medical condition, organ system dysfunction, or other factors
• Hypersensitivity of AT13387 or other components of the drug product
• Treatment with an investigational drug within 3 weeks prior to the first dose of study drug
• Severe systemic diseases or active uncontrolled infections
• Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virus

Where it is running

• University of California, San Diego Medical Center — La Jolla, California, United States
• USC Norris Comprehensive Cancer Center — Los Angeles, California, United States
• UCLA Medical Center — Los Angeles, California, United States
• Sharp Clinical Oncology Research-Sharp Memorial Hospital — San Diego, California, United States
• Innovative Clinical Research Institute — Whittier, California, United States
• University of Colorado Denver — Aurora, Colorado, United States
• Yale University School of Medicine-Yale Cancer Center — New Haven, Connecticut, United States
• Christiana Hospital — Newark, Delaware, United States
• Florida Hospital Cancer Institute — Orlando, Florida, United States
• H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
• Northwestern University The Feinberg School of Medicine — Chicago, Illinois, United States
• University of Chicago — Chicago, Illinois, United States
• Indiana University Melvin and and Bren Simon Cancer Center — Indianapolis, Indiana, United States
• University of Michigan Medical Center — Ann Arbor, Michigan, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Mayo Clinic-Rochester — Rochester, Minnesota, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• University of Nebraska Medical Center Eppley Cancer Center — Omaha, Nebraska, United States
• Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire, United States
• Columbia University Medical Center — New York, New York, United States
• Montefiore Medical Center — The Bronx, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Cone Health Cancer Center — Greensboro, North Carolina, United States
• Oncology Hematology in Cincinnati — Cincinnati, Ohio, United States
• Mayo Clinic-Scottsdale — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.